


AMENDMENTS TO THE CLAIMS

1-74. (Canceled)

75. (Currently amended) A method for treating a ~~Ras/mitogen-activated-protein kinase signal pathway mediated~~ cancer disorder selected from the group consisting of melanoma, breast cancer, prostate cancer, lung cancer, pancreatic cancer, thyroid cancer, bladder cancer, colon cancer, liver cancer, myeloid leukemia, and villous colon adenoma in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of the formula (I) effective to inhibit Raf kinase activity in a human or animal subject:



wherein, X₁ and X₂ are =N- or -NR₄-, provided that if X₁ is -NR₄-, then X₂ is =N-, or if X₂ is -NR₄-, then X₁ is =N-;

Y is O or S;

A₁ is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl;

A₂ is substituted or unsubstituted heteroaryl;

R₁ is O or H, and R₂ is NR₅ R₆ or hydroxyl; or R₁ is taken together with R₂ to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;

R₃ is hydrogen, halogen, loweralkyl, or loweralkoxy;

R₄ is hydrogen, hydroxyl, alkylamino, dialkylamino or alkyl;

R₅ and R₆ are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R₅ and R₆ are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and


R₇ is loweralkyl;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

76. (Currently amended) [[A]] The method of claim 75 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.

77. (Canceled)

78. (Currently amended) A method for treating a Ras/mitogen-activated protein kinase signal pathway-mediated hormone dependent cancer disorder selected from the group consisting of breast cancer and prostate cancer in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of the formula (I) effective to inhibit Raf kinase activity in a human or animal subject:



wherein, X₁ and X₂ are =N- or -NR₄-, provided that if X₁ is -NR₄-, then X₂ is =N-, or if X₂ is -NR₄-, then X₁ is =N-;

Y is O or S;

A₁ is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl;

A₂ is substituted or unsubstituted heteroaryl;

R₁ is O or H, and R₂ is NR₅R₆ or hydroxyl; or R₁ is taken together with R₂ to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;

R₃ is hydrogen, halogen, loweralkyl, or loweralkoxy;

R₄ is hydrogen, hydroxyl, alkylamino, dialkylamino or alkyl;

R₅ and R₆ are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxyalkylheterocyclo, and heteroarylalkyl; or R₅ and R₆ are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and

R₇ is loweralkyl;

or a pharmaceutically acceptable salt, ester or prodrug thereof.


79. (Canceled)

80. (Currently amended) [[A]] The method of claim 78 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.

81. (Canceled)

82. (Previously presented) A method for treating a Ras/mitogen-activated protein kinase signal pathway-mediated hematological cancer disorder in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount

of a compound of the formula (I) effective to inhibit Raf kinase activity in a human or animal subject:



wherein, X_1 and X_2 are =N- or -NR₄-, provided that if X_1 is -NR₄-, then X_2 is =N-, or if X_2 is -NR₄-, then X_1 is =N-;

Y is O or S;

A₁ is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl;

A₂ is substituted or unsubstituted heteroaryl;

R₁ is O or H, and R₂ is NR₅ R₆ or hydroxyl; or R₁ is taken together with R₂ to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;

R₃ is hydrogen, halogen, loweralkyl, or loweralkoxy;

R₄ is hydrogen, hydroxyl, alkylamino, dialkylamino or alkyl;

R₅ and R₆ are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R₅ and R₆ are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and

R₇ is loweralkyl;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

83. (Currently amended) [[A]] The method of claim 82 which further comprises administering to the human or animal subject at least one additional agent for the treatment of

cancer selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.

84-86. (Canceled)

87. (Currently amended) A method of any one of claims 74 through 84 claim 75, 76, 78, 80, 82, or 83, wherein X_1 is NR_4 and X_2 is N in formula (I).

88. (Currently amended) A method of any one of claims 74 through 84 claim 75, 76, 78, 80, 82, or 83, wherein R_4 in formula (I) is hydrogen or C_{1-6} alkyl.

89. (Currently amended) [[A]] The method of claim 88, wherein R_4 in formula (I) is methyl.

90. (Currently amended) A method of any one of claims 74 through 84 claim 75, 76, 78, 80, 82, or 83, wherein Y in formula (I) is O.

91. (Currently amended) A method of any one of claims 74 through 84 claim 75, 76, 78, 80, 82, or 83, wherein A_1 in formula (I) is substituted or unsubstituted C_{3-14} aryl.

92. (Currently amended) [[A]] The method of claim 91, wherein A_1 in formula (I) is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclylcarbonylphenyl, heterocyclylphenyl, heterocyclylalkylphenyl, chlorophenyl, fluorophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylfluorophenyl, trifluoromethylchlorophenyl, trifluoromethylbromophenyl, indenyl, 2,3-dihydroindenyl, tetralinyl, trifluorophenyl, (trifluoromethyl)thiophenyl, alkoxybiphenyl, morpholinyl,

N-piperazinyl, N-morpholinylalkyl, piperazinylalkyl, cyclohexylalkyl, indolyl, 2,3-dihydroindolyl, 1-acetyl-2,3-dihydroindolyl, cycloheptyl, bicyclo[2.2.1]hept-2-yl, hydroxyphenyl, hydroxyalkylphenyl, pyrrolidinyl, pyrrolidin-1-yl, pyrrolidin-1-ylalkyl, 4-amino(imino)methylphenyl, isoxazolyl, indazolyl, adamantyl, bicyclohexyl, quinuclidinyl, imidazolyl, benzimidazolyl, imidazolylphenyl, phenylimidazolyl, pthalamido, naphthyl, benzophenone, aniliny, anisolyl, quinolinyl, quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl, 9H-flouren-1-yl, piperidin-1-yl, piperidin-1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanyl, furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-ylpyridinyl, 4-diazepan-1-yl, hydroxypyrrolidin-1-yl, dialkylaminopyrrolidin-1-yl, 1,4'-bipiperidin-1'-yl, and (1,4'-bipiperidin-1'-ylcarbonyl)phenyl.

93. (Currently amended) A method of any one of claims 74 through 84 claim 75, 76, 78, 80, 82, or 83, wherein A₁ in formula (I) is selected from the group consisting of substituted or unsubstituted phenyl, chlorophenyl, fluorophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylfluorophenyl, trifluoromethylchlorophenyl, trifluoromethylbromophenyl, trifluorophenyl, (trifluoromethyl)thiophenyl, alkoxybiphenyl, hydroxyphenyl, hydroxyalkylphenyl, 4-amino(imino)methylphenyl and (1,4'-bipiperidin-1'-ylcarbonyl)phenyl.

94. (Currently amended) [[A]] The method of claim 93, wherein A₁ in formula (I) is 4-bromophenyl.


95. (Currently amended) [[A]] The method of claim 93, wherein A₁ in formula (I) is trifluoromethylchlorophenyl.

96. (Currently amended) A method of any one of claims 74 through 84 claim 75, 76, 78, 80, 82, or 83, wherein A₂ in formula (I) is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, thiazolyl, indolyl, imidazolyl, oxadiazolyl,

tetrazolyl, pyrazinyl, triazolyl, thiophenyl, furanyl, quinolinyl, purinyl, naphthyl, benzothiazolyl, benzopyridyl and benzoimidazolyl.

97. (Currently amended) ~~[[A]]~~ The method of claim ~~[[95]]~~ 96, wherein A₂ in formula (I) is pyridyl.

98. (Currently amended) ~~[[A]]~~ The method of claim 96, wherein A₂ in formula (I) is



99. (Currently amended) A method of ~~any one of claims 74 through 84~~ claim 75, 76, 78, 80, 82, or 83, wherein R₁ is taken together with R₂ in formula (I) to form a substituted or unsubstituted C₃₋₈ heterocycloalkyl or C₃₋₁₄ heteroaryl group.

100. (Currently amended) A method of ~~any one of claims 74 through 84~~ claim 75, 76, 78, 80, 82, or 83, wherein R₁ is taken together with R₂ in formula (I) to form a group selected from substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, thiazolyl, indolyl, imidazolyl, oxadiazolyl, tetrazolyl, pyrazinyl, triazolyl, thiophenyl, furanyl, quinolinyl, purinyl, naphthyl, benzothiazolyl, benzopyridyl and benzoimidazolyl.

101. (Currently amended) A method of ~~any one of claims 74 through 84~~ claim 75, 76, 78, 80, 82, or 83, wherein R₁ is taken together with R₂ in formula (I) to form a substituted or unsubstituted imidazolyl group.

102. (Currently amended) ~~[[A]]~~ The method of claim 100, wherein the imidazolyl group is substituted with a halo C₁₋₆ alkyl group.

103. (Currently amended) ~~[[A]]~~ The method of claim 100, wherein the imidazolyl group is substituted with a trifluoromethyl group.

104. (Currently amended) A method of any one of claims 74 through 84 claim 75, 76, 78, 80, 82, or 83, wherein R_3 in formula (I) is hydrogen.

105. (Currently amended) A method of any one of claims 74 through 84 claim 75, 76, 78, 80, 82, or 83, wherein R_4 in formula (I) is hydrogen.

106. (Currently amended) A method of any one of claims 74 through 84 claim 75, 76, 78, 80, 82, or 83, wherein R_5 and R_6 in formula (I) are independently selected from hydrogen and methyl.

107. (Canceled)

108. (New) The method of claim 75, wherein the cancer is melanoma.

109. (New) The method of claim 75, wherein the cancer is a carcinoma of the lungs, pancreas, thyroid, bladder or colon.

110. (New) The method of claim 75, wherein the cancer is myeloid leukemia.

111. (New) The method of claim 75, wherein the cancer is villous colon adenoma.